Clinical management of women with genomic BRCA1 and BRCA2 mutations

Breast Cancer Research and Treatment

Volumn 69, Issue 2, 2001, Pages 101-113

  Chang, J ^a   Elledge, R M ^a  

^a Baylor Breast Center   (United States)

Author keywords

BRCA1; BRCA2; Clinical management

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GONADORELIN AGONIST; RETINOID; TAMOXIFEN;

BREAST CANCER; CANCER INCIDENCE; CANCER SCREENING; DNA DAMAGE; FEMALE; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; HISTOPATHOLOGY; HUMAN; LIFESTYLE; MAMMOGRAPHY; MASTECTOMY; OUTCOMES RESEARCH; OVARIECTOMY; OVARY CANCER; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PATIENT CARE PLANNING; PEDIGREE; PHENOTYPE; PROGNOSIS; RISK FACTORS;

EID: 0035175047     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012203917104     Document Type: Review

References (72)

1. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
2. Identification of the breast cancer susceptibility gene BRCA2
3. Comments on: Current policies for surveillance and management in women at risk of breast and ovarian cancer: A survey among 16 European family cancer clinics
4. Recommendations for follow-up care of individuals with an inherited predisposition to cancer, II. BRCA1 and BRCA2: Cancer genetics studies consortium
5. The genetics of breast cancer susceptibility
6. BRCA-1 protein products: Functional motifs
7. From BRCA-1 to RAP-2: A wide-spread BRCT module closely associated with DNA repair
8. Transcriptional activation by BRCA-1
9. The BRC repeats are conserved in mammalian BRCA2 proteins
10. BRCA-2 is required for ionizing radiation-induced assembly of RAD51 complex in vivo
11. Expression of BRC repeats in breast cancer cells disrupts the BRCA2-Rad51 complex and leads to radiation hypersensitivity and loss of G(2)/M checkpoint control
12. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
13. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
14. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women
15. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carrriers of BRCA1 mutations
16. Steroid receptors in hereditary breast carcinomas associated with BRCA-1 or BRCA-2 mutations or unknown susceptibility genes
17. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours
18. Survival in hereditary breast cancer associated with germline mutations of BRCA2
19. BRCA-associated breast cancer: Absence of a characteristic immunophenotype
20. Pathobiologic characteristics of hereditary breast cancer
21. p53 mutations in BRCA1-associated familial breast cancer
22. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability
23. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in BRCA1 and BRCA2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair
24. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations
25. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers
26. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations
27. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1
28. Survival in early-onset BRCA1 breast-cancer patients: Institute Curie Breast Cancer Group
29. Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden
30. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
31. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium
32. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
33. NCCN practice guidelines - Genetics/familial highrisk cancer screening
34. Cohort studies of fat intake and the risk of breast cancer - A pooled analysis
35. Dietary factors and the risk of breast cancer: Combined analysis of 12 case-control studies
36. Soy intake and the risk of breast cancer in Asians and Asian Americans
37. Case-control study of phyto-oestrogens and breast cancer
38. Alcoholic calories, red wine consumption and breast cancer among premenopausal women
39. Alcohol and breast cancer: Update from an Italian case-control study
40. Alcohol consumption in a case-control study of breast cancer in southern France
41. Physical activity and the risk of breast cancer
42. Lifetime exercise activity and breast cancer risk among postmenopausal women
43. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes
44. Risk modifiers in carriers of BRCA1 mutations
45. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2
46. Ten-yeas risk of false positive screening mammograms and clinical breast examinations
47. Dynamic changes of BRCA1 subnuclear locations and phosphorylation state are initiated by DNA damage
48. Randomized trial of breast self-examination in Shanghai: Methodology and preliminary results
49. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
50. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women, Italian Tamoxifen Prevention Study
51. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
52. Breast cancer in relation to nursing and menopausal history
53. The chemoprevention of breast cancer by reducing sex steroid exposure: Perspectives from epidemiology
54. Retinoid chemoprevention studies in upper aerodigestive tract and lung carcinogenesis
55. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
56. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer
57. Breast-duct endoscopy to study stages of cancerous breast disease
58. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
59. Bilateral prophylactic mastectomy (PM) in BRCA1/2 mutation carriers
60. Subcutaneous mastectomy is not a prophylaxis against carcinoma of the breast: Opinion or knowledge?
61. Predictors of and satisfaction with bilateral prophylactic mastectomy
62. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
63. Screening for ovarian cancer: A pilot randomised controlled trial
64. Oral contraceptives and the risk of hereditary ovarian cancer
65. The reduction in risk of ovarian cancer associated with oral contraceptive use: The Cancer and Steroid Hormone Study of the Centers for disease control and the National Institute of Child Health and Human Development
66. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer
67. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
68. Prophylactic, oophorectomy, and ovarian cancer mortality
69. Prophylactic oophorectomy in inherited breast/ovarian cancer families
70. Ovarian cancer risk reduction after bilateral prophylactic oophorectomy (BPO) in BRCA1 and BRCA2 mutation carriers
71. No deleterious effects of radiotherapy in women who are heterozygote for a BRCA-1 or BRCA-2 mutation following breast-conserving therapy
72. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: Implications for breast-conserving management in patients with BRCA1/BRCA2 mutations